Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The central alpha2 adrenergic receptor (α2-AR) is a G protein-coupled receptor (GPCR) primarily associated with the Gi heterotrimeric G-protein. It is activated by endogenous catecholamines such as norepinephrine and epinephrine, playing a crucial role in modulating neurotransmitter release and sympathetic nervous system activity within the central nervous system (CNS). Key subtypes include α2A, α2B, and α2C, each with distinct localization patterns and physiological functions. Therapeutic targeting with selective agonists like clonidine and guanfacine is used for hypertension and anxiety, but side effects such as sedation are common.
Activation leads to Gi protein coupling, inhibiting adenylyl cyclase, decreasing cAMP levels, reducing calcium influx, hyperpolarizing neurons, and inhibiting neurotransmitter release.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Central Alpha2 Adrenergic Receptor (α2-AR).